232 related articles for article (PubMed ID: 32156743)
1. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
[TBL] [Abstract][Full Text] [Related]
7. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
10. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
11. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Sharman JP; Coutre SE; Furman RR; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn IW; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Tausch E; Cramer P; Huang J; Mitra S; Hallek M; O'Brien SM; Stilgenbauer S
J Clin Oncol; 2019 Jun; 37(16):1391-1402. PubMed ID: 30995176
[TBL] [Abstract][Full Text] [Related]
12. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
14. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Puła B; Długosz-Danecka M; Salomon-Perzyński A; Szymczyk A; Subocz E; Budziszewska BK; Rybka J; Gil L; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Zaucha JM; Osowiecki M; Piszczek W; Steckiewicz P; Szukalski Ł; Hus M; Lech-Marańda E; Jurczak W; Jamroziak K
Adv Med Sci; 2020 Sep; 65(2):371-377. PubMed ID: 32659728
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
O'Brien SM; Lamanna N; Kipps TJ; Flinn I; Zelenetz AD; Burger JA; Keating M; Mitra S; Holes L; Yu AS; Johnson DM; Miller LL; Kim Y; Dansey RD; Dubowy RL; Coutre SE
Blood; 2015 Dec; 126(25):2686-94. PubMed ID: 26472751
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
20. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
